Literature DB >> 348614

Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine.

W Kirch, A Distler.   

Abstract

Sixteen patients with essential hypertension were treated with N-Amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride (BS 100--141) and clonidine for five weeks each in a double-blind cross-over trial. Dosage ranged from 2 to 6 mg BS 100--141 and from 0.3 to 0.9 mg clonidine daily in two or three divided doses. Both compounds caused a significant and comparable fall in blood pressure. Patients whose blood pressure was not reduced to normal levels by 2 to 3 mg BS 100--141 daily did not respond better to an increase in the dose. Dry mouth and constipation occurred about equally frequently with both agents, but sedation and orthostatic circulatory effects were considerably more frequent with clonidine. Rebound hypertension likewise occurred in five patients following clonidine withdrawal as opposed to no patient after BS 100-141.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 348614

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  14 in total

1.  Pharmacokinetics of guanfacine in patients undergoing haemodialysis.

Authors:  W Kirch; H Kohler; T Axthelm
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

2.  Clinical experience with guanfacine in long-term treatment of hypertension.

Authors:  P Jerie
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

3.  An ambulatory trial of guanfacine.

Authors:  S Mann; M W Millar Craig; D I Melville; P M Cashman; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

4.  Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine.

Authors:  P Jerie
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

5.  Elimination of guanfacine in patients with normal and impaired renal function.

Authors:  W Kirch; H Köhler; W Braun
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

6.  Blood pressure, heart rate, catecholamines and plasma renin activity following institution and withdrawal of guanfacine treatment in moderate hypertension.

Authors:  P Manhem; B Hökfelt
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

7.  Differences in psychic performance with guanfacine and clonidine in normotensive subjects.

Authors:  J Kugler; R Seus; R Krauskopf; H M Brecht; A Raschig
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

8.  Haemodynamic effects of guanfacine.

Authors:  D Magometschnigg; G Hitzenberger; J Bonelli
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

Review 9.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

10.  Withdrawal of guanfacine after long-term treatment in essential hypertension. Observations on blood pressure and plasma and urinary noradrenaline.

Authors:  C Zamboulis; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.